- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07653685
A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.
A Phase Ib/II Clinical Study to Evaluate the Efficacy and Safety of TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Participants With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.
To assess the safety and preliminary efficacy of TQB2930 and chemotherapy with or without bevacizumab in sparticipants with HER2-Abnormally Expressed locally advanced or metastatic colorectal cancer (CRC).
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
- Medicamento: TQB2930 injection +(Oxaliplatin for injection + Capecitabine tablets)/( Irinotecan hydrochloride injection+ Capecitabine tablets)+Bevacizumab injection
- Medicamento: TQB2930 injection +(Oxaliplatin for injection + Capecitabine tablets)/( Irinotecan hydrochloride injection+ Capecitabine tablets)
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
- Fase 1
Contactos e Locais
Contato de estudo
- Nome: Ruihua Xu, Doctor
- Número de telefone: 020-87343468
- E-mail: xurh@syscc.org.cn
Locais de estudo
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100034
- Ainda não está recrutando
- Peking University First Hospital
-
Contato:
- Shikai Wu, Doctor
- Número de telefone: 15810037307
- E-mail: Skywu4923@sina.com
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, China, 400016
- Ainda não está recrutando
- The First Affiliated Hospital of Chongqing Medical University
-
Contato:
- Tao Zhang, Doctor
- Número de telefone: 13708311156
- E-mail: tumorzzt@163.com
-
-
Gansu
-
Lanzhou, Gansu, China, 730050
- Ainda não está recrutando
- Gansu Provincial Tumor Hospital
-
Contato:
- Zhihu Li, Master
- Número de telefone: 18993042850
- E-mail: 245698692@qq.com
-
-
Guangdong
-
Foshan, Guangdong, China, 528000
- Ainda não está recrutando
- The First People's Hospital of Foshan
-
Contato:
- Wei Wang, Doctor
- Número de telefone: 18038863618
- E-mail: wangwei@fsyyy.com
-
Guangzhou, Guangdong, China, 510060
- Recrutamento
- Sun Yat-sen University Cancer Center
-
Contato:
- Ruihua Xu, Doctor
- Número de telefone: 020-87343468
- E-mail: xurh@syscc.org.cn
-
Guangzhou, Guangdong, China, 510000
- Ainda não está recrutando
- The Sixth Affiliated Hospital, Sun Yat-sen University
-
Contato:
- Yanhon Den, Doctor
- Número de telefone: 13925106525
- E-mail: dengyanh@mail.sysu.edu.cn
-
-
Guangxi
-
Nanning, Guangxi, China, 530000
- Ainda não está recrutando
- Guangxi Zhuang Autonomous Region Cancer Hospital
-
Contato:
- Rong Liang, Doctor
- Número de telefone: 18677070811
- E-mail: 53371159@qq.com
-
-
Guizhou
-
Zunyi, Guizhou, China, 563000
- Recrutamento
- The Affiliated Hospital of Zunyi Medical University
-
Contato:
- Jiwei Wang, Doctor
- Número de telefone: 18013964231
- E-mail: zmu_wangjw@163.com
-
-
Heilongjiang
-
Harbin, Heilongjiang, China, 150000
- Ainda não está recrutando
- Harbin Medical University Cancer Hospital
-
Contato:
- Tongsen Zheng, Doctor
- Número de telefone: 15134569619
- E-mail: zhengtongsen@126.com
-
Contato:
- Yuxian Bai, Doctor
- Número de telefone: 13945095085
- E-mail: bai_yuxian@126.com
-
Qiqihar, Heilongjiang, China, 161005
- Ainda não está recrutando
- Qiqihar First Hospital
-
Contato:
- Xiyuan Sun, Doctor
- Número de telefone: 13945258792
- E-mail: sunxiyuan2004@126.com
-
-
Henan
-
Zhengzhou, Henan, China, 450000
- Ainda não está recrutando
- Henan Cancer Hospital
-
Contato:
- Ying Liu, Doctor
- Número de telefone: 13783604602
- E-mail: yaya7207@126.com
-
Zhengzhou, Henan, China, 450000
- Ainda não está recrutando
- The Third People's Hospital of Zhengzhou
-
Contato:
- HaiCun Wang, Master
- Número de telefone: 13803833783
- E-mail: whc1975@126.com
-
Zhengzhou, Henan, China, 450000
- Ainda não está recrutando
- The first affiliated hospital of Zhengzhou university
-
Contato:
- Yongxu Jia, Doctor
- Número de telefone: 15237128281
- E-mail: fccjiayx@zzu.edu.cn
-
-
Hubei
-
Jingzhou, Hubei, China, 434099
- Ainda não está recrutando
- Jingzhou First People's Hospital
-
Contato:
- Yan Hu, Master
- Número de telefone: 18163137369
- E-mail: helensparkle@163.com
-
Wuhan, Hubei, China, 430022
- Ainda não está recrutando
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
Contato:
- Hongli Liu, Doctor
- Número de telefone: 13995680822
- E-mail: hongliliu@hust.edu.cn
-
-
Hunan
-
Changsha, Hunan, China, 410013
- Recrutamento
- Hunan Cancer Hospital
-
Contato:
- Yi He, Doctor
- Número de telefone: 18692237222
- E-mail: heyi@hnca.org.cn
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210008
- Recrutamento
- Nanjing Drum Tower Hospital
-
Contato:
- Yudong Qiu, Doctor
- Número de telefone: 13951806490
- E-mail: yudongqiu510@163.com
-
Nanjing, Jiangsu, China, 210009
- Recrutamento
- Zhongda Hospital Southeast University
-
Contato:
- CaiLian Wang, Doctor
- Número de telefone: 13851756378
- E-mail: wangcailian65@hotmail.com
-
Nanjing, Jiangsu, China, 210000
- Ainda não está recrutando
- Jiangsu Provincial Cancer Hospital
-
Contato:
- Yuanhua Liu, Doctor
- Número de telefone: 13305180356
- E-mail: yuanhualiu02@hotmail.com
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330000
- Ainda não está recrutando
- Jiangxi Provincal People's Hospital
-
Contato:
- Weirong Yao, Doctor
- Número de telefone: 13907002901
- E-mail: 13907002901@126.com
-
-
Jilin
-
Changchun, Jilin, China, 130021
- Ainda não está recrutando
- Jilin Cancer Hospital
-
Contato:
- Hongxia Cui, Master
- Número de telefone: 13504436090
- E-mail: 2503074283@qq.com
-
Changchun, Jilin, China, 130021
- Ainda não está recrutando
- The first hospital of Jilin University
-
Contato:
- Tingting Liang, Doctor
- Número de telefone: 15804303776
- E-mail: liangting2006@163.com
-
-
Liaoning
-
Shenyang, Liaoning, China, 110000
- Recrutamento
- Liaoning Cancer Hospital & Institute
-
Contato:
- Jingdong Zhang, Doctor
- Número de telefone: 18040007878
- E-mail: 13804027878@163.com
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710000
- Ainda não está recrutando
- The First Affiliated Hospital of Xi'an Jiaotong University Medical College
-
Contato:
- Aili Suo, Doctor
- Número de telefone: 18991232561
- E-mail: Ailisuo@mail.xjtu.edu.cn
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200127
- Recrutamento
- Renji Hospital, Shanghai Jiao Tong University School of Medicine
-
Contato:
- XiuYing Xiao, Doctor
- Número de telefone: 13564579313
- E-mail: xiaoxiuying2002@163.com
-
-
Shanxi
-
Xi’an, Shanxi, China, 710000
- Ainda não está recrutando
- The Second Affiliated Hospital of Air Force Medical University
-
Contato:
- Haichuan Su, Doctor
- Número de telefone: 18629190366
- E-mail: cntdgcp@163.com
-
Xi’an, Shanxi, China, 710000
- Ainda não está recrutando
- The First Affiliated Hospital of Air Force Medical University
-
Contato:
- Yongzhan Nie, Doctor
- Número de telefone: 15091520001
- E-mail: nieyongzhan@qq.com
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, China, 300202
- Recrutamento
- Tianjin Medical University Cancer Institute & Hospital
-
Contato:
- Zhanyu Pan, Master
- Número de telefone: 18622221256
- E-mail: tjpanzy@126.com
-
Tianjin, Tianjin Municipality, China, 300121
- Ainda não está recrutando
- Tianjin Union Medical Center
-
Contato:
- Mingqing Zhang, Doctor
- Número de telefone: 15122875158
- E-mail: zmq1003@163.com
-
-
Xinjiang
-
Ürümqi, Xinjiang, China, 830054
- Ainda não está recrutando
- Xinjiang Medical University Affiliated Tumor Hospital
-
Contato:
- YanLi Qu, Master
- Número de telefone: 18160627963
- E-mail: quyanli73@163.com
-
-
Zhejiang
-
Lishui, Zhejiang, China, 323000
- Recrutamento
- Lishui Municipal Central Hospital
-
Contato:
- Yanru Xie, Master
- Número de telefone: 13567615770
- E-mail: 43437677@qq.com
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Participants voluntarily participate in this study, sign the informed consent form, and have good compliance
- Age: 18-75 years (including the boundary when signing the informed consent form)
- Eastern Cooperative Oncology Group (ECOG) score: 0-1
- Expected survival of more than 3 months
- Unresectable locally advanced or metastatic colorectal cancer diagnosed by histopathology/cytology
- HER2-Abnormally Expressed tested
- Presence of at least one measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
- Participants should agree to use contraception during the study and for 6 months after the end
Exclusion Criteria:
- Participants with previously confirmed Microsatellite Instability Microsatellite Instability-High Deficient Mismatch Repair (MSI-H/dMMR)
- Presence of conditions affecting intravenous, venous blood sampling, or multiple factors affecting oral medications
- Active inflammatory bowel disease within 28 days prior to first dose
- Other malignancies within 5 years prior to the first dose or currently suffering from other malignancies
- Unresolved toxicity greater than CTCAE Grade 1 due to any prior therapy
- Major surgical treatment, significant traumatic injury within 28 days prior to the first dose or anticipation of major surgery during study treatment
- Had wounds or fractures that had not been healed for a long time
- Cerebrovascular accident, deep venous thrombosis and pulmonary embolism within 6 months prior to the first dose
- Patients with a history of psychotropic substance abuse who cannot quit or have mental disorders
- Participants with any severe and/or uncontrolled disease
- Known tumor-related carcinomatous meningitis with symptoms of brain metastases or symptom control for less than 4 weeks
- Patients with imaging suggestive of tumor invasion of major blood vessels or fatal massive hemorrhage due to tumor rupture or invasion of major blood vessels judged by the investigator to be very likely to occur during the study
- Failure to control serous effusions requiring repeated drainage
- Local radiotherapy or 4. Bone marrow irradiation > 30% for bone metastasis before the first medication
- Known tumor-related spinal cord compression, weight-bearing bone pathological fracture, extensive bone metastasis, or uncontrollable tumor bone metastasis-related pain
- Patients who have received chemotherapy, targeted therapy, immunotherapy or other systemic anti-tumor drug therapy before the first medication;
- Received Chinese patent medicine treatment with anti-tumor indications in the package insert of National Medical Products Administration (NMPA) approved drugs before study treatment
- History of live attenuated vaccination before the first dose or planned live attenuated vaccination during the study;
- Previous history of severe allergy of unknown origin
- According to the investigator's judgment, there are concomitant diseases that seriously endanger the participants' safety or affect the completion of the study, or the participant is considered unsuitable for other reasons
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: TQB2930 injection +chemotherapy + Bevacizumab injection
|
TQB2930 enhances the binding to HER2 protein on the surface of tumor cells and increases HER2 internalization by simultaneously targeting ECD2 and ECD4, two non-overlapping epitopes of HER2 protein, which in turn more effectively down-regulates HER2 protein on the surface of tumor cells and dually blocks HER2 signaling. Oxaliplatin can block DNA replication and transcription and induce tumor cell apoptosis. Irinotecan hydrochloride injection inhibits topoisomerase-I via its active metabolite SN-38, prevents religation of DNA single-strand breaks, causes irreversible DNA double-strand damage and induces tumor cell apoptosis. Capecitabine inhibits thymidylate synthase (TS) and interferes with DNA synthesis. Bevacizumab blocks VEGF binding to receptors and inhibits tumor angiogenesis. |
|
Comparador Ativo: TQB2930 injection +chemotherapy
|
TQB2930 enhances the binding to HER2 protein on the surface of tumor cells and increases HER2 internalization by simultaneously targeting ECD2 and ECD4, two non-overlapping epitopes of HER2 protein, which in turn more effectively down-regulates HER2 protein on the surface of tumor cells and dually blocks HER2 signaling. Oxaliplatin can block DNA replication and transcription and induce tumor cell apoptosis. Irinotecan hydrochloride injection inhibits topoisomerase-I via its active metabolite SN-38, prevents religation of DNA single-strand breaks, causes irreversible DNA double-strand damage and induces tumor cell apoptosis. Capecitabine inhibits thymidylate synthase (TS) and interferes with DNA synthesis. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Recommended Phase 2 Dose
Prazo: Baseline up to 21 days
|
It refers to the safe and effective dose range that can be used for phase II study determined through phase I clinical trial. |
Baseline up to 21 days
|
|
Adverse event (AE)
Prazo: From the participants signing of the informed consent form to 28 days after the last dose or the start of new anti-tumor therapy (whichever occurs first)
|
Incidence and severity of adverse events. |
From the participants signing of the informed consent form to 28 days after the last dose or the start of new anti-tumor therapy (whichever occurs first)
|
|
Objective Response Rate
Prazo: Baseline up to 24 months
|
The proportion of participants achieving complete response and partial response among the total evaluable cases. |
Baseline up to 24 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Half-life
Prazo: Baseline up to 24 months
|
The time it takes for the concentration of a drug in the body (usually the plasma concentration) to decrease to half of its initial value. |
Baseline up to 24 months
|
|
Plasma concentration-time profiles
Prazo: Baseline up to 24 months
|
Total area covered under the curve plotted with time as X-axis and plasma concentration as Y-axis. |
Baseline up to 24 months
|
|
Apparent clearance
Prazo: Baseline up to 24 months
|
The rate at which the drug is cleared from the body. |
Baseline up to 24 months
|
|
Apparent terminal volume of distribution
Prazo: Baseline up to 24 months
|
Describe the drug distribution in the body. |
Baseline up to 24 months
|
|
Trough plasma concentration
Prazo: Baseline up to 24 months
|
Minimum plasma drug concentration level at the end of the dosing interval (before the next dosing). |
Baseline up to 24 months
|
|
Disease Control Rate
Prazo: Baseline up to 24 months
|
The percentage of participants with a complete response, partial response, or stable disease as determined by RECIST 1.1. |
Baseline up to 24 months
|
|
Duration Of Response
Prazo: Baseline up to 24 months
|
The time from the first assessment of the tumor as a complete response or partial response to the first occurrence of disease progression or death from any cause. |
Baseline up to 24 months
|
|
Progression Free Survival
Prazo: Baseline up to 24 months
|
Progression Free Survival (PFS) is defined as the length of time from the start of treatment until the disease progresses or the patient dies from any cause. |
Baseline up to 24 months
|
|
Overall Survival
Prazo: Baseline up to 24 months
|
The time from the start of initial treatment to death from any cause. |
Baseline up to 24 months
|
|
Anti-Drug Antibodies (ADA) incidence
Prazo: Baseline up to 24 months
|
Proportion of anti-drug antibody produced in the population of patients using the drug. |
Baseline up to 24 months
|
Colaboradores e Investigadores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Neoplasias por local
- Neoplasias
- Doenças Intestinais
- Neoplasias gastrointestinais
- Neoplasias do Aparelho Digestivo
- Doenças do aparelho digestivo
- Doenças Gastrointestinais
- Neoplasias Intestinais
- Doenças retais
- Doenças do cólon
- Neoplasias Colorretais
- Terapêutica
- Rotas de administração de medicamentos
- Terapia medicamentosa
- Injeções
Outros números de identificação do estudo
- TQB2930-Ib/II-02
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .